{
  "id": 6728666,
  "title": "Stifel sees CMS TAVR coverage update as positive for Edwards",
  "url": "https://urgent.news/2026/09/11/stifel-sees-cms-tavr-coverage-update-as-positive-for-edwards",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-11T08:13:30.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/stifel-sees-cms-tavr-coverage-update-as-positive-for-edwards-93CH-4897357"
  },
  "original_language": "en",
  "account": "CMS recently released an updated TAVR national coverage determination, which closely resembles the June proposal document. Stifel analysts believe this final decision is favorable for the overall TAVR market and particularly beneficial for Edwards Lifesciences due to the company's market leadership position. TAVR represents a significant portion of Edwards' revenues, accounting for over 75% of the company's income and around 5.5% of Medtronic's revenues.\n\nIn addition, CMS announced it is currently conducting a national coverage analysis for TAVR devices that treat aortic regurgitation, including Edwards' J-Valve and the privately held, FDA-approved JenaValve. This analysis is expected to be completed by June 8, 2027. The final decision reaffirms CMS's support for TAVR in asymptomatic aortic stenosis patients, which was one of the key factors driving the national coverage determination re-opening.\n\nCMS maintains the heart team's role in evaluating aortic stenosis patients, emphasizing the importance of the cardiac surgeon's involvement. The finalized decision allows for the asynchronous use of medical records to determine patient suitability for TAVR or alternative treatments, although patients still require an in-person evaluation and the cardiac surgeon's participation. Stifel views this update as a net positive for the TAVR market, as it enables greater scheduling efficiency by reducing the need for a surgeon to be present in the operating room during the procedure.\n\nThe final decision maintains the TAVR volume requirement standards outlined in the proposal document. Medicare has eliminated the coverage with evidence development requirement for all severe aortic stenosis patients, except for those in the newly supported asymptomatic severe aortic stenosis group. Stifel analysts believe this update aligns with Edwards' long-range plan for revenue growth, as well as the company's pipeline innovations and competitive advantages.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}